Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
299 participants
INTERVENTIONAL
2006-11-09
2007-09-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder
NCT00273039
A Combination Therapy In Patients With Social Anxiety Disorder
NCT00403962
Social Anxiety Disorder Study Of Paroxetine
NCT00318669
Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder
NCT00191022
Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder
NCT00074802
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GW876008
paroxetine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* have a history of Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder.
18 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Beverly Hills, California, United States
GSK Investigational Site
Burbank, California, United States
GSK Investigational Site
Temecula, California, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Orlando, Florida, United States
GSK Investigational Site
Smyrna, Georgia, United States
GSK Investigational Site
Oakbrook Terrace, Illinois, United States
GSK Investigational Site
Rockville, Maryland, United States
GSK Investigational Site
Farmington Hills, Michigan, United States
GSK Investigational Site
Nutley, New Jersey, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
Media, Pennsylvania, United States
GSK Investigational Site
Edmonton, Alberta, Canada
GSK Investigational Site
Kelowna, British Columbia, Canada
GSK Investigational Site
Miramichi, New Brunswick, Canada
GSK Investigational Site
Mississauga, Ontario, Canada
GSK Investigational Site
Kuopio, , Finland
GSK Investigational Site
Rauma, , Finland
GSK Investigational Site
Turku, , Finland
GSK Investigational Site
Hüttenberg, Hesse, Germany
GSK Investigational Site
Achim, Lower Saxony, Germany
GSK Investigational Site
Göttingen, Lower Saxony, Germany
GSK Investigational Site
Westerstede, Lower Saxony, Germany
GSK Investigational Site
Berlin, , Germany
GSK Investigational Site
Hamar, , Norway
GSK Investigational Site
Oslo, , Norway
GSK Investigational Site
Sandvika, , Norway
GSK Investigational Site
Tygerberg, Eastern Cape, South Africa
GSK Investigational Site
Durban, , South Africa
GSK Investigational Site
Observatory ,Cape Town, , South Africa
GSK Investigational Site
Gothenburg, , Sweden
GSK Investigational Site
Malmo, , Sweden
GSK Investigational Site
Uppsala, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRH103390
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.